Syndax Pharmaceuticals, Inc. reported significant financial developments in its latest 10-Q filing for the third quarter of 2025, showcasing a marked increase in revenue and ongoing operational adjustments. The company generated total revenues of $45.9 million for the three months ended September 30, 2025, a substantial increase from $12.5 million in the same period last year. This growth was primarily driven by product revenue from its recently launched drug, Revuforj, which accounted for $32.0 million in net sales, alongside collaboration revenue of $13.9 million from its partnership with Incyte for the drug Niktimvo. For the nine months ending September 30, 2025, total revenues reached $103.6 million, compared to $16.0 million in the prior year.
Despite the revenue growth, Syndax reported a net loss of $60.7 million for the third quarter, an improvement from the $84.1 million loss recorded in the same quarter of 2024. The company’s total operating expenses increased slightly to $103.3 million, up from $102.1 million year-over-year, with notable increases in selling, general, and administrative expenses, which rose by $13.8 million due to costs associated with the commercialization of Revuforj and Niktimvo. Research and development expenses decreased by $14.7 million, reflecting the completion of certain clinical trials and a reduction in costs related to revumenib.
Syndax has also made strategic advancements, including the recent FDA approval of Revuforj for treating relapsed or refractory acute myeloid leukemia (AML) with a specific mutation, marking a significant milestone for the company. The approval, announced on October 24, 2025, is expected to enhance the product's market presence and drive further revenue growth. Additionally, the company has been actively involved in clinical trials for both Revuforj and Niktimvo, with ongoing studies aimed at expanding their therapeutic applications.
As of September 30, 2025, Syndax reported total assets of $551.8 million, a decrease from $724.8 million at the end of 2024, primarily due to reduced cash and investment balances. The company’s cash and cash equivalents stood at $116.8 million, down from $154.1 million at the end of the previous year. The decrease in cash was attributed to increased operational expenditures and investments in clinical trials. Syndax's accumulated deficit has now reached $1.4 billion, reflecting its ongoing investment in research and development.
Looking ahead, Syndax remains focused on leveraging its recent product approvals and expanding its clinical pipeline. The company anticipates continued investment in research and development, particularly for its lead products, while also exploring opportunities for additional collaborations and licensing agreements to enhance its market position. The management expressed confidence that the combination of existing cash reserves and anticipated revenue from product sales will support its operational needs in the near term.
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals is a biopharmaceutical company focused on developing innovative cancer therapies. Its core products include FDA-approved revumenib for acute leukemia and axatilimab for chronic graft-versus-host disease, with ongoing clinical programs in oncology and fibrotic diseases. The company leverages licensing, collaborations, and a strong pipeline to address unmet medical needs in hematology, oncology, and fibrosis markets worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.